BCAB
Price
$0.41
Change
-$0.04 (-8.89%)
Updated
Feb 21 closing price
Capitalization
23.68M
25 days until earnings call
SPRO
Price
$0.83
Change
-$0.01 (-1.19%)
Updated
Feb 21 closing price
Capitalization
45.33M
18 days until earnings call
Ad is loading...

BCAB vs SPRO

Header iconBCAB vs SPRO Comparison
Open Charts BCAB vs SPROBanner chart's image
BioAtla
Price$0.41
Change-$0.04 (-8.89%)
Volume$895.71K
Capitalization23.68M
Spero Therapeutics
Price$0.83
Change-$0.01 (-1.19%)
Volume$82.07K
Capitalization45.33M
BCAB vs SPRO Comparison Chart
Loading...
BCAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SPRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BCAB vs. SPRO commentary
Feb 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCAB is a Buy and SPRO is a Buy.

Ad is loading...
COMPARISON
Comparison
Feb 24, 2025
Stock price -- (BCAB: $0.47 vs. SPRO: $0.82)
Brand notoriety: BCAB and SPRO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCAB: 85% vs. SPRO: 32%
Market capitalization -- BCAB: $23.68M vs. SPRO: $45.33M
BCAB [@Biotechnology] is valued at $23.68M. SPRO’s [@Biotechnology] market capitalization is $45.33M. The market cap for tickers in the [@Biotechnology] industry ranges from $393.7B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCAB’s FA Score shows that 1 FA rating(s) are green whileSPRO’s FA Score has 1 green FA rating(s).

  • BCAB’s FA Score: 1 green, 4 red.
  • SPRO’s FA Score: 1 green, 4 red.
According to our system of comparison, SPRO is a better buy in the long-term than BCAB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCAB’s TA Score shows that 5 TA indicator(s) are bullish while SPRO’s TA Score has 5 bullish TA indicator(s).

  • BCAB’s TA Score: 5 bullish, 2 bearish.
  • SPRO’s TA Score: 5 bullish, 2 bearish.
According to our system of comparison, both BCAB and SPRO are a good buy in the short-term.

Price Growth

BCAB (@Biotechnology) experienced а +17.74% price change this week, while SPRO (@Biotechnology) price change was -0.02% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.27%. For the same industry, the average monthly price growth was +3.99%, and the average quarterly price growth was +2.35%.

Reported Earning Dates

BCAB is expected to report earnings on May 08, 2025.

SPRO is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (+4.27% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SPRO($45.3M) has a higher market cap than BCAB($23.7M). SPRO YTD gains are higher at: -20.282 vs. BCAB (-30.971). SPRO has higher annual earnings (EBITDA): -2.45M vs. BCAB (-85.17M). SPRO has more cash in the bank: 76.3M vs. BCAB (56.5M). BCAB has less debt than SPRO: BCAB (1.25M) vs SPRO (4.62M). SPRO has higher revenues than BCAB: SPRO (89.9M) vs BCAB (11M).
BCABSPROBCAB / SPRO
Capitalization23.7M45.3M52%
EBITDA-85.17M-2.45M3,481%
Gain YTD-30.971-20.282153%
P/E RatioN/A10.39-
Revenue11M89.9M12%
Total Cash56.5M76.3M74%
Total Debt1.25M4.62M27%
FUNDAMENTALS RATINGS
SPRO: Fundamental Ratings
SPRO
OUTLOOK RATING
1..100
58
VALUATION
overvalued / fair valued / undervalued
1..100
43
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
80
PRICE GROWTH RATING
1..100
89
P/E GROWTH RATING
1..100
5
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
BCABSPRO
RSI
ODDS (%)
Bullish Trend 6 days ago
90%
Bullish Trend 6 days ago
80%
Stochastic
ODDS (%)
Bullish Trend 6 days ago
81%
Bullish Trend 6 days ago
79%
Momentum
ODDS (%)
Bullish Trend 6 days ago
81%
Bullish Trend 6 days ago
69%
MACD
ODDS (%)
N/A
Bullish Trend 6 days ago
79%
TrendWeek
ODDS (%)
Bullish Trend 6 days ago
81%
Bullish Trend 6 days ago
75%
TrendMonth
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 6 days ago
90%
Advances
ODDS (%)
Bullish Trend 6 days ago
81%
N/A
Declines
ODDS (%)
Bearish Trend 21 days ago
90%
Bearish Trend 17 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 6 days ago
82%
Bullish Trend 6 days ago
86%
Aroon
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 6 days ago
89%
View a ticker or compare two or three
Ad is loading...
BCAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SPRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SPY611.491.79
+0.29%
SPDR® S&P 500® ETF Trust
AAPL244.47-0.13
-0.05%
Apple
GME26.97-0.03
-0.11%
GameStop Corp
BTC.X95539.550000-233.835940
-0.24%
Bitcoin cryptocurrency
TSLA354.11-1.73
-0.49%
Tesla

BCAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCAB has been loosely correlated with TECH. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if BCAB jumps, then TECH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCAB
1D Price
Change %
BCAB100%
-9.03%
TECH - BCAB
39%
Loosely correlated
-0.87%
CTMX - BCAB
39%
Loosely correlated
-4.42%
DNLI - BCAB
38%
Loosely correlated
-3.98%
NKTR - BCAB
36%
Loosely correlated
-2.58%
STOK - BCAB
34%
Loosely correlated
-4.69%
More

SPRO and

Correlation & Price change

A.I.dvisor tells us that SPRO and TECH have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SPRO and TECH's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SPRO
1D Price
Change %
SPRO100%
+0.75%
TECH - SPRO
31%
Poorly correlated
-0.99%
ABOS - SPRO
31%
Poorly correlated
N/A
BCAB - SPRO
30%
Poorly correlated
+0.84%
GNPX - SPRO
29%
Poorly correlated
-7.01%
OLMA - SPRO
28%
Poorly correlated
+1.41%
More